Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Therapeutic potential of adipose-derived mesenchymal stem/stromal cells conditioned medium versus adipose-derived mesenchymal stem/stromal cells on treatment of polycystic ovary In-vivo.

Abou-El-Naga A., Elarby NY., Sobh MA., Mutawa G.

Animal Study on Type 2 Diabetes, published in Tissue Cell (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Tissue Cell (2026)
Country
Scotland
Reported sample size
—
Source database
PubMed
PMID
42202461
DOI
10.1016/j.tice.2026.103634

Abstract (original English)

Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder characterized by ovulatory dysfunction and insulin resistance. Adipose tissue-derived Mesenchymal stem/stromal cell (Ad-derived MSCs)-based therapies have shown promising regenerative effects in PCOS models. However, most cell-free therapeutic investigations have primarily focused on MSC-derived exosomes, whereas the therapeutic potential of the complete conditioned medium (CM), which contains a broader spectrum of secreted bioactive factors, remains underexplored. Therefore, this study aimed to compare the therapeutic efficacy of Ad-derived MSCs and their CM in a letrozole-induced PCOS female rat (four groups: control, PCOS, Ad-derived MSCs-treated, and Ad-derived MSCs-CM-treated). Hormonal profiling, reproductive performance, and estrous cyclicity were monitored. Metabolic parameters comprised the insulin resistance index (HOMA-IR) and lipid profile markers. Glutathione and malondialdehyde as oxidative stress biomarkers, Annexin V/PI and Caspase-3 as apoptotic markers, and inflammatory mediators were evaluated alongside histological and immunohistochemical examination of ovarian and uterine tissues. PCOS induction produced endocrine imbalance, insulin resistance, dyslipidemia, oxidative stress, and increased apoptosis with marked ovarian and uterine structural alterations. Both Ad-derived MSCs an

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
FemaleAnimalsPolycystic Ovary SyndromeMesenchymal Stem CellsCulture Media, ConditionedAdipose TissueRatsLetrozoleOxidative StressMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research